Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy

Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately-held biotechnology company focused on the development of macrophage-based immunotherapeutics, today announced the close of a $53 million Series A financing to further expand its technology platform and rapidly drive its programs toward clinical development. The financing was led by AbbVie Ventures and HealthCap and includes existing seed investors IP Group, Penn Medicine and Grazia Equity.   Carisma is also proud to welcome new investors Wellington Partners, TPG Biotech, MRL Ventures Fund and Agent Capital.

The case for Narcan and CPR training

ImmERge Labs cofounder Marion Leary was walking home from the Philadelphia Eagles parade last Thursday, amid a city overcome with joy when, suddenly, she bumped into the very problem her startup is trying to fix.

Surrounded by police officers and a small crowd, a middle-age overdose victim lay motionless on a North Philly sidewalk.

A woman was atop the victim, delivering compressions to the center of their chest. Despite her poor technique, the good Samaritan was trying to bring the victim back to life, as first responders waited for the Narcan to kick in.

naviHealth Acquires RightCare Solutions

naviHealth, Inc., a Cardinal Health company, today announced the acquisition of RightCare Solutions, Inc., a healthcare decision support software service provider specializing in hospital discharge planning software and readmissions management. RightCare’s software is powered by proprietary, evidence-based decision-support technology developed in conjunction with the University of Pennsylvania School of Nursing.